A new somatic mutation in the coding region of Kirsten rat sarcoma viral oncogene homolog gene (KRAS), G48A, has been identified in a patient with non-small cell lung cancer (NSCLC). No other mutations were found by screening several genes known to be mutated in NSCLC. The patient responded to first-line therapy and is still under maintenance treatment 18 months after diagnosis. Normal and cancer cells were engineered to express the KRAS(G48A) mutation. KRAS(G48A) overexpression did not change the growth or the response to treatment compared with KRAS(wild type)-expressing cells. Analysis of the structure of the KRAS(G48A) mutant predicted altered interactions with other proteins. Analysis of KRAS binding to B-Raf proto-oncogene, serine/thr...
Lung cancer represents commonest cancer worldwide, with a high mortality rate as the disease becomes...
BACKGROUND: Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the deve...
KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung...
A new somatic mutation in the coding region of Kirsten rat sarcoma viral oncogene homolog gene (KRAS...
In non-small cell lung cancer (NSCLC) the most common alterations are identified in the Kirsten rat ...
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene mutations are among the most common driver al...
Approximately 30 % of all human cancers have a mutation in the v-Ki-ras2 Kirsten rat sarcoma viral o...
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSC...
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung cancer (NSCLC...
The development of covalent inhibitors against KRAS G12C represents a major milestone in treatment o...
Background: Lung cancer is the leading cause of cancer-related death and one of the most common canc...
KRAS is the most frequently mutated oncogene identified in human cancers. Despite the numerous effor...
Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be related with...
Lung cancer is the leading cause of cancer deaths. Tumor heterogeneity, which hampers development of...
Background:Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be related with ...
Lung cancer represents commonest cancer worldwide, with a high mortality rate as the disease becomes...
BACKGROUND: Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the deve...
KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung...
A new somatic mutation in the coding region of Kirsten rat sarcoma viral oncogene homolog gene (KRAS...
In non-small cell lung cancer (NSCLC) the most common alterations are identified in the Kirsten rat ...
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene mutations are among the most common driver al...
Approximately 30 % of all human cancers have a mutation in the v-Ki-ras2 Kirsten rat sarcoma viral o...
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSC...
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung cancer (NSCLC...
The development of covalent inhibitors against KRAS G12C represents a major milestone in treatment o...
Background: Lung cancer is the leading cause of cancer-related death and one of the most common canc...
KRAS is the most frequently mutated oncogene identified in human cancers. Despite the numerous effor...
Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be related with...
Lung cancer is the leading cause of cancer deaths. Tumor heterogeneity, which hampers development of...
Background:Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be related with ...
Lung cancer represents commonest cancer worldwide, with a high mortality rate as the disease becomes...
BACKGROUND: Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the deve...
KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung...